Gyre Therapeutics, Inc. Common Stock
GYREGyre Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies targeting neurological and neurodegenerative disorders. Utilizing advanced drug delivery platforms, Gyre aims to address unmet medical needs through novel treatments that improve patient outcomes.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 12, 2023 | $0.24 | 2023-01-13 | 2023-01-05 |
| September 20, 2022 | $1.43 | 2022-09-21 | 2022-09-06 |
| August 19, 2015 | $0.57 | 2015-08-20 | 2015-08-14 |
Dividends Summary
- Consistent Payer: Gyre Therapeutics, Inc. Common Stock has rewarded shareholders with 3 dividend payments over the past 8 years.
- Total Returned Value: Investors who held GYRE shares during this period received a total of $2.24 per share in dividend income.
- Latest Payout: The most recent dividend of $0.24/share was paid 1107 days ago, on January 12, 2023.
- Dividend Growth: Since 2015, the dividend payout has decreased by 57.8%, from $0.57 to $0.24.
Company News
Gyre Therapeutics reported Q3 2025 net income of $5.9 million, with quarterly revenue of $30.6 million, up 20% year-over-year. The company revised full-year revenue guidance to $115-118 million due to delayed product rollouts and procurement uncertainties.
Gyre Therapeutics will present positive Phase 3 clinical trial results for Hydronidone, a novel anti-fibrotic agent targeting liver fibrosis in chronic hepatitis B, at AASLD's The Liver Meeting® 2025 in Washington D.C.
Gyre Therapeutics announced the appointment of Dr. Dan Weng to its Board of Directors, bringing nearly four decades of clinical trial management experience. The company is focused on developing fibrosis treatments and has a prominent product in the Chinese market.
Gyre Therapeutics announced the first dosing in a Phase 1 clinical trial of its novel drug F230 for the treatment of pulmonary arterial hypertension (PAH) in China. This milestone marks Gyre's entry into the PAH field, a rare and high-mortality condition with limited treatment options.
Gyre Therapeutics, a biotechnology company, announced the pricing of its public offering of 2,222,222 shares of common stock at $9.00 per share, with an option for underwriters to purchase an additional 333,333 shares. The company plans to use the net proceeds to advance its clinical trial and for general corporate purposes.
